The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. LENZ Therapeutics Inc shares valued at $10,150,000 were sold by Versant Venture Capital VI, L. on Jun 10 ’25. At $29.00 per share, Versant Venture Capital VI, L. sold 350,000 shares. The insider’s holdings dropped to 1,248,789 shares worth approximately $37.5 million following the completion of this transaction.
Analysts at TD Cowen started covering the stock with ‘”a Buy”‘ outlook in a report released in mid March. As of September 27, 2024, Raymond James has initiated its “an Outperform” rating for LENZ. Earlier on August 12, 2024, H.C. Wainwright initiated its rating. Their recommendation was “a Buy” for LENZ stock.
Analyzing LENZ Stock Performance
On last trading session,, LENZ Therapeutics Inc [NASDAQ: LENZ] rose 3.69% to $30.03. The stock’s lowest price that day was $28.68, but it reached a high of $30.755 in the same session. During the last five days, there has been a surge of approximately 0.10%. Over the course of the year, LENZ Therapeutics Inc shares have jumped approximately 4.02%. Shares of the company reached a 52-week high of $33.42 on 06/09/25 and a 52-week low of $16.53 on 04/09/25.
Support And Resistance Levels for LENZ Therapeutics Inc (LENZ)
According to the 24-hour chart, there is a support level at 28.89, which, if violated, would cause prices to drop to 27.75. In the upper region, resistance lies at 30.96. The next price resistance is at 31.90. RSI (Relative Strength Index) is 55.10 on the 14-day chart, showing neutral technical sentiment.
Is LENZ Therapeutics Inc subject to short interest?
Stocks of LENZ Therapeutics Inc saw a sharp rise in short interest on 2025-05-30 jumping by 0.14 million shares to 3.33 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 3.19 million shares. A jump of 4.26% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 17.72 of the overall float, the days-to-cover ratio (short ratio) jumped to 17.72.
Which companies own the most shares of LENZ Therapeutics Inc (LENZ)?
In terms of LENZ Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 51 in the next 12 months, up nearly 76.1% from the previous closing price of $28.96. Analysts anticipate LENZ Therapeutics Inc stock to reach 51 by 2025, with the lowest price target being 51. In spite of this, 2 analysts ranked LENZ Therapeutics Inc stock as Buy at the end of 2025.
